ARTICLE

DS16570511 is a small-molecule inhibitor of the mitochondrial calcium uniporter

Naohiro Kon1, Michiko Murakoshi2, Aya Isobe3, Katsuji Kagechika4, Naoki Miyoshi4 and Takahiro Nagayama5

In cardiac myocytes, regulation of mitochondrial Ca\(^{2+}\) is important for cellular signaling and cardiac contraction. Ca\(^{2+}\) entry into the mitochondria is mediated by a highly selective Ca\(^{2+}\) channel called the mitochondrial calcium uniporter, which consists of a pore-forming subunit MCU and regulatory subunits such as MICU1. Although pharmacological regulation of the mitochondrial Ca\(^{2+}\) influx is a promising approach to controlling the cellular functions, a cell-permeable and specific inhibitor of the mitochondrial calcium uniporter has not yet been developed. Here, we identify a novel cell-permeable inhibitor of the uniporter by a high-throughput screening of 120,000 small-molecule compounds. In our study, DS16570511 dose-dependently inhibited serum-induced mitochondrial Ca\(^{2+}\) influx in HEK293A cells with an IC\(_{50}\) of 7 \(\mu\)M. DS16570511 inhibited Ca\(^{2+}\) uptake of isolated mitochondria from human cells, rat heart and pig heart. Overexpression of hMCU or hMICU1 in HEK293A cells increased mitochondrial Ca\(^{2+}\) influx, and the increases were completely suppressed by the pretreatment with DS16570511. DS16570511 also blocks mitochondrial Ca\(^{2+}\) overload in a Langendorff perfused beating rat heart. Interestingly, DS16570511 increased cardiac contractility without affecting heart rate in the perfused heart. These results show that DS16570511 is a novel cell-permeable inhibitor of the mitochondrial calcium uniporter and applicable for control of the cardiac functions.

Cell Death Discovery (2017) 3, 17045; doi:10.1038/cddiscovery.2017.45; published online 17 July 2017

INTRODUCTION

Mitochondria store large amounts of Ca\(^{2+}\) for cellular Ca\(^{2+}\) homeostasis and regulation of cytosolic Ca\(^{2+}\) signaling.1,2 Mitochondrial membrane potential generated by the electron transport chain is the driving force of the Ca\(^{2+}\) uptake.3–5 The Ca\(^{2+}\) influx into the mitochondria is mediated by an inward-rectifying, highly selective Ca\(^{2+}\) channel called the mitochondria calcium uniporter. Although molecular components of the uniporter have been completely unknown for a long time, recent studies have revealed that the Muc gene encodes a channel-forming unit of the uniporter. MCU is a mitochondrial inner membrane protein, and the multimer forms a Ca\(^{2+}\) channel in the lipid bilayer.6 In addition, the uniporter activity is positively or negatively tuned by some regulatory subunits such as MICU1.7–10 MICU1 is a calcium-binding EF-hand-containing protein that regulates the uniporter activity in a Ca\(^{2+}\) concentration-dependent manner. MICU1 functions as a gatekeeper of the uniporter by inhibiting MCU activity at resting Ca\(^{2+}\) levels, whereas it has a stimulatory role in agonist-challenged cultured cells.11 At present, the regulatory mechanism of the uniporter activity is still under discussion.

The identification of the genetic component of the mitochondrial uniporter has provided new opportunities to understanding the biological roles of mitochondrial Ca\(^{2+}\) regulation.1,2,10,12–15 For example, in isolated cardiomyocytes, siRNA-mediated knockdown of Muc enhances peak levels in cytosolic Ca\(^{2+}\) oscillation, which results in an increase of muscle contraction.16 In pathological aspects such as acute ischemia-reperfusion, cellular injury caused by mitochondrial Ca\(^{2+}\) overload is protected by cardiomyocyte-specific knockout of the Muc gene in mice.14,17 Importantly, recent human genetic study has shown that mutation of MICU1 causes brain and muscle disorders.18 This study showed that fibroblasts of patients exhibited increased mitochondrial Ca\(^{2+}\) influx. Therefore, excess Ca\(^{2+}\) influx into mitochondria is toxic for cells and tissues in both acute and chronic pathological situations.

The physiological and pathological evidences suggest that inhibition of the mitochondrial calcium uniporter activity is a novel and unique approach to controlling the cellular functions or to treating mitochondrial diseases. The most well-known inhibitors of the mitochondrial calcium uniporter are the polycationic compounds, Ruthenium Red (RuR) and Ruthenium 360 (Ru360). The Ca\(^{2+}\) channel activity mediated by recombinant MCU multimers in the lipid bilayer is inhibited by RuR, showing that RuR directly acts on MCU to inhibit the channel activities.8 Although RuR potently inhibits the uniporter activities, its pharmacological use is limited owing to two factors: (1) the impermeability of the plasma membrane and (2) its unspecific inhibitory action against various ion channels.9 Therefore, cell-permeability and identifying the specific inhibitor of the uniporter are very important in pharmacology; although, no specific chemical uniporter inhibitor has yet been reported.

In the present study, we performed a high-throughput screening for small-molecule inhibitors of the mitochondrial Ca\(^{2+}\) influx in HEK293A cells. We found that DS16570511 blocked the Ca\(^{2+}\) influx in the cultured cells and isolated mitochondria. DS16570511 blocked the MCU- or MICU1-dependent increases of Ca\(^{2+}\) influx. Isolated perfused heart experiments revealed that the novel inhibitor has an inotropic effect in addition to the protective effect against mitochondrial Ca\(^{2+}\) overload.
RESULTS

DS16570511 is a novel cell-permeable inhibitor of mitochondrial Ca\(^{2+}\) influx

To obtain cell-permeable inhibitors of the mitochondrial calcium uniporter, we generated a human cell-based assay for high-throughput screening (HTS). HEK293A cell lines expressing the mitochondria-targeted Ca\(^{2+}\) indicator protein aequorin were established to detect dynamic mitochondrial Ca\(^{2+}\) influx. By using the cell-based assay as the first screening system, we screened 120,000 small-molecule compounds. The screening flow of this exploratory project is depicted in Supplementary Figure S1, and five criteria were set to obtain hit compounds: (1) IC\(_{50}\) of the hits was to be below 10 \(\mu M\) in the cell-based mitochondrial Ca\(^{2+}\) influx assay. (2) IC\(_{50}\) in the mitochondrial assay was to be at least sevenfold smaller than the IC\(_{50}\) in a counter assay using cytosol-targeted aequorin (this is an indicator of specificity to the mitochondrial calcium uniporter). (3) The inhibitory activity was to be observed in isolated mitochondria from the human cells. (4) The inhibition was also to be observed in mitochondria prepared from small and large animals (in this case rats and pigs). (5) The inhibitory activity was to be reproducibly observed in the resynthesized compound. We found that DS16570511 was the only one of the hit compounds meeting all of these criteria (Supplementary Figures S2 and S3).

In the first screening using the cell-based assay, application of 10\% fetal bovine serum to the cells triggered a rapid increase of mitochondrial Ca\(^{2+}\) level (Figure 1a). Pretreatment of the cells with DS16570511 inhibited the serum-induced mitochondrial Ca\(^{2+}\) influx with an IC\(_{50}\) of 7 \(\mu M\) (Figures 1a and b). In order to eliminate broad channel inhibitors or chemicals affecting the aequorin-based detection system, a counter assay was carried out using HEK293A cells expressing aequorin in cytosol. In the assay, the concentration of DS16570511 used to decrease the serum-induced cytosolic Ca\(^{2+}\) increase by 50\% was ~50 \(\mu M\). These results indicated that DS16570511 is a selective inhibitor of mitochondrial Ca\(^{2+}\) influx in human cultured cells.

DS16570511 inhibits Ca\(^{2+}\) uptake activity of isolated mitochondria.

Mitochondrial Ca\(^{2+}\) uptake activity is regulated by cytosolic protein kinase signaling, raising the possibility that HTS hits contained indirect inhibitors of the uniporter, such as inhibitors of cytosolic signaling. To examine the direct inhibitory effect of the compounds on the mitochondrial Ca\(^{2+}\) uptake, isolated mitochondria from HEK293A cells were used. Ca\(^{2+}\) uptake of the isolated mitochondria was observed as a rapid increase in the luminescence level after application of 100 \(\mu M\) Ca\(^{2+}\) (Figure 2a). In the assay, Ru360, a positive control of this assay, inhibited the Ca\(^{2+}\) uptake activity with an IC\(_{50}\) of 0.02 \(\mu M\) (Figure 2b), and we observed dose-dependent inhibition of the Ca\(^{2+}\) uptake by DS16570511 with an IC\(_{50}\) of 0.86 \(\mu M\). These results indicated that DS16570511 directly inhibits the human mitochondrial calcium uniporter.

We then asked whether DS16570511 inhibits Ca\(^{2+}\) uptake in isolated mitochondria from animal heart. An atomic absorbence spectrometer-based detection method was employed to analyze intramitochondrial Ca\(^{2+}\) levels. We prepared freshly isolated mitochondria from pig heart, and the mitochondria were incubated with 100 \(\mu M\) CaCl\(_2\). Intramitochondrial Ca\(^{2+}\) levels were significantly increased by the Ca\(^{2+}\) incubation (Figure 3a). The increase was fully blocked by the pretreatment of positive control RuR with an IC\(_{50}\) of 0.03 \(\mu M\), and DS16570511 blocked the Ca\(^{2+}\) uptake activity of the pig heart mitochondria with an IC\(_{50}\) of 15 \(\mu M\) (Figure 3b). When mitochondria from rat hearts was used for this assay, the IC\(_{50}\)S of RuR and DS16570511 were 0.1 and 25 \(\mu M\), respectively (Figure 3c). These results showed that DS16570511 blocks Ca\(^{2+}\) uptake by the isolated mitochondria in both small and large animals. Because the IC\(_{50}\) of DS16570511 in the human mitochondria (Figure 2b) was smaller than that of pigs and rats (Figures 3b and c), it is possible that DS16570511 more potently inhibits the uniporter of humans than it inhibits the uniporter of pigs or rats.

Inhibitory effect of DS16570511 is not dependent on disruption of mitochondrial membrane potential.

Next we analyzed the mechanism of action of DS16570511. The previous studies implicated two possible inhibitory mechanisms for the mitochondrial Ca\(^{2+}\) uptake: (1) direct blockade of the calcium uniporter and (2) disruption of the membrane potential. Mitochondrial Ca\(^{2+}\) uptake is mediated by electrical potential across the mitochondrial inner membrane, which is generated by the oxidative phosphorylation system. Consistent with the previous studies, we observed that carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), an uncoupler of the mitochondrial membrane potential, significantly inhibited the Ca\(^{2+}\) uptake activity of isolated pig heart mitochondria (Figure 4a). To examine effects on the mitochondrial membrane potential, fluorescent indicator JC-10 was used in mitochondria from pig heart. As previously described, incubation of fresh pig heart mitochondria with FCCP resulted in disruption of the potential in a
Figure 2. DS16570511 inhibits Ca^{2+} uptake in isolated mitochondria from HEK293A cells. (a) Representative raw data of Ca^{2+} uptake in isolated mitochondria. (b) Effect of DS16570511 or Ru360 on mitochondrial Ca^{2+} uptake. The area under the curve of temporal aequorin activities is used for calculation of inhibitory activities. Inhibition 0 or 100% is defined as a value of Ca^{2+}-untreated cells or Ca^{2+}-treated cells, respectively. Data are mean with S.E.M. from three independent samples.

Figure 3. DS16570511 inhibits Ca^{2+} uptake in isolated heart mitochondria. (a) Effect of RuR on Ca^{2+} uptake of pig heart mitochondria. Y axis shows intramitochondrial Ca^{2+} levels (ng) per 1 mg mitochondrial protein. Data are mean with S.E.M. from three independent samples. (b) Inhibition rate of RuR or DS16570511 on Ca^{2+} uptake of pig heart mitochondria. Inhibition 0 or 100% is defined as a value of Ca^{2+}-untreated mitochondria or Ca^{2+}-treated mitochondria, respectively. Data are mean with S.E.M. from three independent samples. (c) Inhibition rate of RuR or DS16570511 on Ca^{2+} uptake of rat heart mitochondria. Data are mean with S.E.M./variation from three or two independent samples for DS16570511 or RuR, respectively.
A novel inhibitor of the mitochondrial calcium uniporter
N Kon et al

Figure 4. DS16570511 has no effect on mitochondrial membrane potential. (a) Effect of FCCP on Ca^{2+} uptake of pig heart mitochondria. (b) Effect of FCCP, Ru360 or DS16570511 on membrane potential of pig heart mitochondria. Relative membrane potential 0 or 100% is defined as value of 1 μM FCCP-treated mitochondria or vehicle-treated mitochondria, respectively. Data are mean with S.E.M. from three (a) or four (b) independent samples.

Dose-dependent manner (Figure 4b). On the other hand, Ru360 had no effect on the membrane potential. Therefore, the assay is useful for classifying inhibitors into two types, the uncoupler type compound or the blocker type compound. Importantly, the mitochondrial membrane potential was not reduced by treatment with DS16570511 (Figure 4b), showing that DS16570511 is a blocker type compound like Ru360.

DS16570511 inhibits MCU- or MICU1-dependent increase of mitochondrial Ca^{2+} influx
Next, to investigate the molecular component of the mitochondrial calcium uniporter, MCU-dependent and MICU-dependent Ca^{2+} influx were examined. Exogenously overexpressed MCU significantly increased mitochondrial Ca^{2+} influx in HEK293A cells (Figure 5a), which was consistent with the previous studies.9,10 The MCU-dependent increment of Ca^{2+} influx was blocked by the DS16570511 pretreatment (Figure 5b). We then investigated the effects of the inhibitor on the regulatory subunit MICU1. Previous studies have shown that MICU1 facilitates mitochondrial MCU-dependent increment of Ca^{2+} influx in the isolated heart (Figure 6, compare lane 1 with lane 4). Furthermore, DS16570511 dose-dependently inhibited the mitochondrial Ca^{2+} overload induced by 7.5 mM Ca^{2+} buffer (Figure 6, compare lane 5 with lanes 6 to 8). These results showed that DS16570511 is applicable to an ex vivo working heart for inhibition of mitochondrial Ca^{2+} overload.

We then investigated the effect of DS16570511 on cardiac functions in the perfused heart. We observed that heart rate was unaffected by DS16570511 in the range of 3–30 μM (Figure 7a). Interestingly, we found that the treatment of DS16570511 increased cardiac contractility in the perfused heart (Figures 7b and c). The increase of contractility was diminished by washout of the drug (Figure 7b), showing that the cardiac effect of DS16570511 is reversible. These results indicated that DS16570511 is a novel inhibitor of the mitochondrial calcium uniporter, which also exerts a positive inotropic action.

DISCUSSION
Since the discovery of the inhibitory action of RuR against mitochondrial Ca^{2+} uptake, the compound has been used to investigate the relationship between Ca^{2+} entry into the mitochondrial matrix and the function of the organelle. Recently, several compounds known to exhibit a cellular protective effect have been reported to show inhibitory effects on the uniporter. KB-R7943, originally developed as an inhibitor of plasma membrane Na^{+}/Ca^{2+} exchange, was found to inhibit the agonist-induced mitochondrial Ca^{2+} influx in Hela cells.24 NecroX-5, one of the derivatives of the reactive oxygen species scavenger NecroX series compounds, was found to attenuate Ca^{2+} accumulation in cultured myocytes.25 And it was demonstrated that antibiotic minocycline inhibits Ca^{2+} uptake in isolated rat liver mitochondria.26 Original findings of these compounds did not indicate them as being specific inhibitors of the uniporter, and the compounds have additional biochemical actions.24,27,28 Therefore, we started exploratory research seeking a small-molecule inhibitor that acts directly against the uniporter by developing novel screening methods. The present study identifies DS16570511 as a cell-permeable and selective inhibitor applicable to a series of experiments using isolated mitochondria, cultured cells and an ex vivo perfused heart.

We found that DS16570511 inhibits endogenous activities of mitochondrial Ca^{2+} uptake (Figures 1–3). In addition, it inhibits Ca^{2+} uptake driven by exogenously expressed MCU or MICU1 (Figure 5). Both components of the uniporter complex have been demonstrated as being essential for mitochondrial Ca^{2+} uptake activity. Therefore, both MCU and MICU1 are potential binding
targets of DS16570511. As the regulatory mechanism of the uniporter activities is still unclear at present, DS16570511 is useful as a novel chemical biological tool for understanding the molecular machinery of the uniporter complex.

In drug development research, it is important to confirm whether biological activities shown by a molecular biological study are also observed in the experiments using a molecularly targeted drug. Knockdown of 

\[ \text{Mcu} \]

by siRNA has been shown to increase contractility in isolated cardiac cells. Consistent with this study, DS16570511 increased cardiac contractility in the isolated perfused heart (Figure 7). On the other hand, several studies have reported that knockout mice of 

\[ \text{Mcu} \]

show no overt baseline phenotype in cardiac functions. It is possible that acute inhibition such as siRNA-mediated knockdown or pharmacological inhibition (Figure 7) is important to the exerting of the inotropic action on the heart.

Mitochondrial 

\[ \text{Ca}^{2+} \]

influx is important to the controlling of cell death events. Inhibition of MCU protects mouse neurons from NMDA receptor-dependent excitotoxicity. Recent studies have demonstrated that cardiac specific knockout of MCU shows protection against the injury in vivo. This is consistent with a number of pharmacological and genetic studies showing potent protective effects of blocking mitochondrial permeability transition in the injury. Importantly, human genetic study has revealed that mutation of 

\[ \text{MICU1} \]

causes mitochondrial 

\[ \text{Ca}^{2+} \]

overload, which promotes the development of brain and muscle disorders. Because DS16570511 potently blocks both MCU-dependent and MICU1-dependent 

\[ \text{Ca}^{2+} \]

overload (Figure 5), the compound may be an effective treatment for such genetic disorders, as well as for cardiac ischemia-reperfusion injury.

The present study identified a cell-permeable chemical inhibitor of the mitochondrial calcium uniporter and demonstrated that the uniporter activity is adjustable by the compound in the intact tissue. DS16570511 is a potential lead compound and its further study should serve to open up new avenues to satisfying unmet medical needs in mitochondrial diseases.

**MATERIALS AND METHODS**

**Animals and reagents**

Nine-week-old male Wistar rats were purchased from Japan SLC (Hamamatsu, Japan). All experimental procedures were performed in accordance with the in-house guidelines of the Institutional Animal Care and Use Committee of Daiichi Sankyo. The animals received a standard laboratory diet and filtered water ad libitum under specific pathogen-free conditions. Every effort was made to minimize animal suffering and to reduce the number of animals employed. All animal studies were also conducted in accordance with the ARRIVE guidelines. The following were also purchased: fresh pig hearts from Tokyo Shibaura Zouki Co., Ltd. (Tokyo, Japan); pIREs-puro vector from Clontech Laboratories, Inc. (Mountain View, CA, USA); HEK293A cells, pcDNA3.1, Hanks Balanced Salt Solution, coelenterazine h and a mitochondria isolation kit from Thermo Fisher Scientific Inc. (Waltham, MA, USA); fetal bovine serum and RuR from
Sigma-Aldrich, Inc. (St Louis, MO, USA); JC-10 from Enzo Life Sciences, Inc. (Farmingdale, NY, USA).

Aequorin assay
For dynamic measurements of mitochondrial Ca\(^{2+}\) levels in intact cells, HEK293A cells were stably transfected with pIRES-puro vector expressing mitochondria-targeted aequorin.20 One day after plating on a 15-cm dish (8 × 10\(^6\) cells/dish), the cells were harvested and incubated with 2.5 \(\mu\)M coelenterazine h in aequorin assay buffer (200 mM Hanks Balanced Salt Solution, 25 mM HEPES (pH 7.0) and 0.1% bovine serum albumin) for 2 h at room temperature. The cells (8.1 × 10\(^4\) cells/well) were then treated with DS16570511 for 20 min in a 96-well plate at room temperature. For induction of intracellular Ca\(^{2+}\), the cells were treated with 10% fetal bovine serum, and luminescence levels were measured by using a Centro LB960 luminometer (Berthold Technologies, Oak Ridge, TN, USA).

In order to evaluate mitochondrial Ca\(^{2+}\) uptake activity by MCU or MICU1, HEK293A cells were transiently transfected with the mitochondria-targeted aequorin vector and pcDNA3.1 vector containing human Mucl (NCBI Reference Sequence: NM_138357.2) or Micu1 (NM_001195518.1). One day after the transfection, the luminescence levels were measured as described above. MCU- or MICU1-dependent activity was calculated by subtracting the luminescence level of cells transfected with empty vector from that of cells expressing MCU or MICU1, respectively.

To monitor Ca\(^{2+}\) uptake activity of isolated mitochondria, mitochondria were prepared from the cells (1 × 10\(^8\) cells) stably expressing mitochondria-targeted aequorin by using a mitochondria isolation kit. The mitochondrial pellet was suspended in 12 ml of swelling buffer (150 mM sucrose, 50 mM KCl, 2 mM KH\(_2\)PO\(_4\), 5 mM succinic acid and 20 mM Tris (pH 7.4)) containing 2.5 \(\mu\)M coelenterazine h. Five minutes after incubation of the mitochondria solution with DS16570511 in a 96-well plate at room temperature, CaCl\(_2\) (final concentration of 100 \(\mu\)M) was applied to the solution. The luminescence levels were detected as described above.

Ca\(^{2+}\) uptake assay using isolated heart mitochondria
Mitochondria were isolated by using the mitochondria isolation kit and then dissolved in the swelling buffer. The protein concentration of the mitochondrial solution was 5 mg/ml. Thirty minutes after application of CaCl\(_2\) (final concentration of 100 \(\mu\)M) to the solution, the mitochondria were collected by centrifugation (3000 g) at 4 °C. The pellets were resuspended in the swelling buffer containing 1 \(\mu\)M RuR. After collection of the mitochondria by centrifugation (3000 g), the pellets were dried and dissolved by 40 \(\mu\)l of sulfuric acid at 95 °C. The solution was then diluted by water, and Ca\(^{2+}\) concentration of the solution was measured by atomic absorbance spectrometer (Hitachi High-Technologies Corporation, Z-2710, Tokyo, Japan).

Mitochondrial membrane potential assay
Pig heart mitochondria were prepared as described above and suspended in the swelling buffer containing 1 \(\mu\)M JC-10. The protein concentration of the solution was 5 mg/ml. Five minutes after incubation of the mitochondria with DS16570511 at room temperature, fluorescence intensities were measured by a FlexStation 3 (Molecular Devices, LLC, Sunnyvale, CA, USA) using the green channel (excitation/emission wavelength: 485/538 nm) or the red channel (excitation/emission wavelength: 485/612 nm).
Rat isolated perfused heart assay

The hearts were rapidly excised from 9-week-old male Wistar rats and perfused at 37 °C with Krebs-Ringer perfusion buffer (127.2 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 25 mM NaHCO₃ and 5.5 mM glucose (pH 7.4)) equilibrated with 95% O₂/5% CO₂. A balloon was inserted through the left atrium into the left ventricle. Heart rate and contractility were continuously recorded with a data acquisition system (PowerLab, ADInstruments, Bella Vista, NSW, Australia).

ACKNOWLEDGEMENTS

The study was sponsored by Daichi Sankyo Co., Ltd, Tokyo, Japan. We appreciate Derek Frampton Davis for review of this manuscript.

AUTHOR CONTRIBUTIONS

NK, MM and AI performed the experiments and analyzed the data; NK, MM, KK, NM and TN designed the study; NK led the project and prepared the manuscript.

COMPETING INTEREST

The authors declare no conflict of interest.

REFERENCES

1 Rizzuto R, De Stefani D, Raffaello A, Mammucari C. Mitochondria as sensors and regulators of calcium signalling. Nat Rev Mol Cell Biol 2012; 13: 566–578.
2 Fosket JK, Philipson B. The mitochondrial Ca²⁺-uniporter complex. J Mol Cell Cardiol 2015; 78: 3–8.
3 DeLuca HF, Engstrom GW. Calcium uptake by rat kidney mitochondria. Proc Natl Acad Sci USA 1961; 47: 1744–1750.
4 Vasington FD, Murphy JV. Ca ion uptake by rat kidney mitochondria. J Biol Chem 1962; 237: 2670–2677.
5 Kirichok Y, Kravivinsky G, Clapham DE. The mitochondrial calcium uniporter is a highly selective ion channel. Nature 2004; 427: 360–364.
6 Kamer KJ, Mootha VK. The molecular era of the mitochondrial calcium uniporter. Nat Rev Mol Cell Biol 2015; 16: 545–553.
7 Perocchi F, Gohil VM, Girgis HS, Bao XR, McCombs JE, Palmer AE. MICU1 encodes a mitochondrial EF hand protein required for Ca²⁺ uptake. Nature 2010; 467: 291–296.
8 De Stefani D, Raffaello A, Teardo E, Szabó I, Rizzuto R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 2010; 467: 336–340.
9 Baughman JM, Perocchi F, Girgis HS, Plovanch M, Belcher-Timme CA, Sancak Y et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 2011; 476: 341–345.
10 Pan X, Liu J, Nguyen T, Liu C, Sun J, Teng Y et al. The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat Cell Biol 2013; 15: 1464–1472.
11 Patron M, Checchetto V, Raffaello A, Teardo E, Vecellio Reane D, Manton M et al. MICU1 and MICU2 finely tune the mitochondrial Ca²⁺ uniporter by exerting opposite effects on MCU activity. Mol Cell 2014; 53: 726–737.
12 Wu Y, Rasmussen TP, Koval OM, Joiner ML, Hall DO, Chen B et al. The mitochondrial uniporter controls flight or flight heart rate increases. Nat Commun 2015; 6: 6081.
13 Holmström KM, Pan X, Liu JC, Menazza S, Liu J, Nguyen TT et al. Assessment of cardiac function in mice lacking the mitochondrial calcium uniporter. J Mol Cell Cardiol 2015; 85: 178–182.
14 Kwong IJ, Lu X, Cornell RN, Schwanekamp JA, Vagnozzi RJ, Sargent MA et al. The mitochondrial calcium uniporter selectively matches metabolic output to acute contractile stress in the heart. Cell Rep 2015; 12: 15–22.
15 Rasmussen TP, Wu Y, Joiner ML, Koval OM, Wilson NR, Luczak ED et al. Inhibition of MCU forces extramitochondrial adaptations governing physiological and pathological stress responses in heart. Proc Natl Acad Sci USA 2015; 112: 9129–9134.
16 Drago I, De Stefani D, Rizzuto, Pozzan T. Mitochondrial Ca²⁺ uptake contributes to buffering cytoplasmic Ca²⁺ peaks in cardiomyocytes. Proc Natl Acad Sci USA 2012; 109: 12986–12991.
17 Luongo TS, Lambert JP, Yuan A, Zhang X, Gross P, Song J et al. The mitochondrial calcium uniporter matches energetic supply with cardiac workload during stress and modulates permeability transition. Cell Rep 2015; 12: 23–34.
18 Logan CV, Szabadkai G, Sharpe JA, Parry DA, Torelli S, Childs AM et al. Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signalling. Nat Genet 2014; 46: 188–193.
19 Joiner ML, Koval OM, Li J, He BJ, Allamargot C, Gao Z et al. CalMKI determines mitochondrial stress responses in heart. Nature 2012; 491: 269–273.
20 Patron M, Raffaello A, Granatiiero V, Tosatto A, Merli G, De Stefani D et al. The mitochondrial calcium uniporter (MCU): molecular identity and physiological roles. J Biol Chem 2013; 288: 10750–10758.
21 Paupe V, Prudent J, Dassa EP, Rondoz OZ, Shoubridge EA. CCDC90A (MCUR1) is a cytochrome c oxidase assembly factor and not a regulator of the mitochondrial calcium uniporter. Cell Metab 2015; 21: 109–116.
22 Waldeck-Weiermair M, Malli R, Parichatikomand W, Gottschalk B, Madreiter-Sokolowski CT, Klec C et al. Rearrangement of MICU1 multimers for activation of MCU is solely controlled by cytosolic Ca²⁺. Sci Rep 2015; 5: 15602.
23 Olejnícikova V, Novakova M, Provaznik I. Isolated heart models: cardiovascular system studies and technological advances. Med Biol Eng Comput 2015; 53: 669–678.
24 Santo-Domingo J, Vay L, Herméndez-Sammiguel E, Lobatón CD, Moreno A, Alvarez J. The plasma membrane Na⁺/Ca²⁺ exchanger inhibitor KB-R7943 is also a potent inhibitor of the mitochondrial Ca²⁺ uniporter. Br J Pharmacol 2007; 151: 647–654.
25 Thu VT, Kim HK, Long T, Lee SR, Hanh TM, Ko TH et al. NecroX-5 prevents hypoxia/reoxygenation injury by inhibiting the mitochondrial calcium uniporter. Cardiovasc Res 2012; 94: 342–350.
26 Schwartz J, Holmuhamedov E, Zhang X, Lovelace GL, Smith CD, Lembarski JJ. Minocycline and doxycycline, but not other tetracycline-derived compounds, protect liver cells from chemical hypoxia and ischemia/reperfusion injury by inhibition of the mitochondrial calcium uniporter. Toxicol Appl Pharmacol 2013; 273: 172–179.
27 Kim HU, Koo SY, Ahn BH, Park O, Park DH, Seo DO et al. NecroX as a novel class of mitochondrial reactive oxygen species and ONOO⁻ scavenger. Arch Pharm Res 2010; 33: 1813–1823.
28 Antonenko VN, Rokitskaya TI, Cooper AJ, Krasnikov BF. Minocycline chelates Ca²⁺, binds to membranes, and depolarizes mitochondria by formation of Ca²⁺-dependent ion channels. J Bioenerg Biomembr 2010; 42: 151–163.
29 Vadman M. NIH mulls rules for validating key results. US biomedical agency could enlist independent labs for verifying experiments: the ARRIVE guidelines. Nature 2013; 500: 14–16.
30 Qiu J, Tan YW, Hagenston AM, Martel MA, Kneisel N, Skehel PA. Mitochondrial calcium uniporter Mcu controls excitotoxicity and is transcriptionally repressed by neuroprotective nuclear calcium signals. Nat Commun 2013; 4: 2034.
31 Bernardi P, Di Lisa F. The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection. J Mol Cell Cardiol 2015; 78: 100–106.
32 Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 2010; 160: 1577–1579.
33 McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 2010; 160: 1573–1576.

Supplementary Information accompanies the paper on the Cell Death Discovery website (http://www.nature.com/cddiscovery)